Catalyst Pharmaceuticals (CPRX) Receivables - Net (2010 - 2026)

Catalyst Pharmaceuticals' Receivables - Net history runs 9 years deep, the most recent figure standing at $130.8 million for Q1 2026.

• Quarterly Receivables - Net rose 83.59% year-over-year to $130.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.8 million (up 83.59% YoY) and the FY2025 annual result came in at $126.5 million, up 93.17% from the prior year.
• Receivables - Net was $130.8 million for Q1 2026 at Catalyst Pharmaceuticals, up from $126.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $130.8 million in Q1 2026 and bottomed at $9.3 million in Q3 2022.
• A 5-year average of $56.5 million and a median of $57.2 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2023 — Receivables - Net soared 414.61% — and 2025, when it advanced 15.2%.
• Catalyst Pharmaceuticals' Receivables - Net stood at $10.4 million in 2022, then jumped by 412.64% to $53.5 million in 2023, then climbed by 22.35% to $65.5 million in 2024, then surged by 93.17% to $126.5 million in 2025, then grew by 3.44% to $130.8 million in 2026.
• Business Quant data shows CPRX's Receivables - Net at $130.8 million in Q1 2026, $126.5 million in Q4 2025, and $106.4 million in Q3 2025.